Jiang Yao, Guo Zhenhua, Weng Maoyang, Chen Linlin, Li Qingmei, Zhang Lei, Qiao Songlin, Zhang Gaiping
College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, China.
Key Laboratory of Animal Immunology of the Ministry of Agriculture, Institute for Animal Health, Henan Academy of Agricultural Sciences, Zhengzhou, China.
Front Microbiol. 2025 Mar 5;16:1546925. doi: 10.3389/fmicb.2025.1546925. eCollection 2025.
Senecavirus A (SVA) is an emerging vesicular pathogen in swine with clinical signs similar to those of foot-and-mouth disease, porcine vesicular disease and vesicular stomatitis, making the control of swine vesicular disease outbreaks difficult. Therefore, the development of effective diagnostics and vaccines for SVA has become critical. VP2 is a structural protein that elicits a strong immune response, which positions it a candidate for diagnostic and vaccine development.
In this study, five high-titer monoclonal antibodies (mAbs) were produced using hybridoma technology. Twenty-eight peptides covering the entire VP2 sequence were synthesised by overlapping peptide synthesis, and the positive peptides were screened with the five mAbs by ELISA and Dot-blotting. The peptides were then further truncated to identify the minimal epitope regions based on immunoinformatics analyses.
Four mAbs were identified that reacted with peptide 15 and one mAb reacted with peptide 26. Further truncation of these peptides led to the identification of two novel minimal epitopes: 156-NEEQWV-161 and 262-VRPTSPYFN-270. Structural and sequence alignment analyses revealed that epitope 156-NEEQWV-161 is located in the flex-loop region of the VP2, whereas epitope 262-VRPTSPYFN-270 is located in the β-sheet of the VP2. Both epitopes were highly conserved among typical SVA isolates from different countries.
This study identifies two novel B-cell epitopes on the VP2, contributing to the development of VP2-based diagnostic tools with clinical applications. The findings also provide valuable material for the design of novel vaccines against SVA, offering new insights into the immune response to this pathogen.
A 型塞内卡病毒(SVA)是一种在猪中出现的水疱性病原体,其临床症状与口蹄疫、猪水疱病和水疱性口炎相似,这使得控制猪水疱病疫情变得困难。因此,开发针对 SVA 的有效诊断方法和疫苗变得至关重要。VP2 是一种能引发强烈免疫反应的结构蛋白,这使其成为诊断和疫苗开发的候选对象。
在本研究中,利用杂交瘤技术制备了五种高滴度单克隆抗体(mAb)。通过重叠肽合成法合成了覆盖整个 VP2 序列的 28 个肽段,并通过 ELISA 和斑点印迹法用这五种 mAb 筛选阳性肽段。然后基于免疫信息学分析对这些肽段进行进一步截短,以确定最小表位区域。
鉴定出四种与肽段 15 反应的 mAb 和一种与肽段 26 反应的 mAb。对这些肽段的进一步截短导致鉴定出两个新的最小表位:156-NEEQWV-161 和 262-VRPTSPYFN-270。结构和序列比对分析表明,表位 156-NEEQWV-161 位于 VP2 的柔性环区域,而表位 262-VRPTSPYFN-270 位于 VP2 的β-折叠中。这两个表位在来自不同国家的典型 SVA 分离株中高度保守。
本研究在 VP2 上鉴定出两个新的 B 细胞表位,有助于开发具有临床应用价值的基于 VP2 的诊断工具。这些发现还为设计针对 SVA 的新型疫苗提供了有价值的材料,为深入了解对该病原体的免疫反应提供了新的见解。